Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan 2023-08-09 13:00
Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S. 2023-04-11 13:00
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS 2023-03-25 02:51
Pharming announces first patient enrolled in pediatric clinical trial of leniolisib 2023-02-21 14:00
Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe 2023-02-16 14:00
Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition 2022-12-15 14:00
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood 2022-12-07 14:00
Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib 2022-10-28 13:00
Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib 2022-10-11 13:00
Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib 2022-09-28 13:00
Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency 2022-08-02 13:00
Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS 2022-08-01 13:00
Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting 2022-04-01 23:45
1